

DAFTAR PUSTAKA


1. Reksodiputro AH, Irawan C. Limfoma non Hodgkin dalam Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. Buku Ajar Ilmu Penyakit Dalam Jilid I. Edisi VI. Jakarta; Pusat Penerbitan Ilmu Penyakit Dalam. 2014; 1251–60
2. Freedman AS, Nadler LM. Limfoma Maligna dalam Iseelbacher, Braunwald, Wilson, Martin, Fauci, Kesper. Harrison Prinsip-prinsip ilmu penyakit dalam. Edisi ke-3. Jakarta; EGC. 2000; 1973–8.
3. Sutrisno, H. Gambaran kualitas hidup pasien kanker limfoma non-hodgkin yang dirawat di RSUP Sanglah Denpasar. *Jurnal Penyakit Dalam*. 2010; 96–102.
4. KEMENKES RI. Data dan kondisi penyakit limfoma di Indonesia. Pusat Data dan Informasi KEMENKES RI.2015
5. Perdana OP. Insiden Penyakit Hodgkin di laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 1997-Desember 2001. Padang; Fakultas Kedokteran Universitas Andalas. 2002
6. Karin S. Epidemiology and etiology of non-hodgkin lymphoma. *Acta Oncologica*. 2006; 45: 258–71
7. Schn LH, Optimal use of prognostic factors in Non Hodgkin Lymphoma. *Journal of hematology*.2016; 298 – 302.
8. Xie R, Tang J, Hu S, Jiang H. Diffuse large B cell lymphoma-related prognostic factors, Ki-67 and Bcl-6 *Expression Levels*.*BMC Cancer*.2017. 28 (15);6740 – 6742.
9. Schinasi L, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. *Int J Environ Res Public Health*.2014;4449–527
10. Tao LL, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer. *Molecular Medicine Reports*.2015; 1566–1572.
11. Menon SS, Guruvayoorappan C, Sakhvirer KM, Rasmi RR. Ki-67 protein as a tumor proliferation marker. *Clinica Chimica Acta*.2019;01–11

12. Gupta M, Witzig T. Signal transduction inhibitor therapy for lymphoma. *Hematology Am Soc Hematol Educ Program NIH Public Access*. 2013; 265–70
13. Lin TY, Zheng A, Huang Y, Wang HQ, Liu Y, Zhu J. Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B cell lymphoma in China a multicenter randomized trail. *Pubmed J* 2005;24: 1421–6
14. Kahl B. Chemotherapy combination with monoclonal antibodies in non hodgkin lymphoma. *Semin Hematol*.2008;90–4
15. Lin TY, Zheng A, Huang Y, Wang HQ, Liu Y, Zhu J. Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B cell lymphoma in China a multicenter randomized trail. *Pubmed J* 2005;1421–6
16. Liu Z1, Xu Z, Cao X, Manyam G, Wang X. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. *Mod Pathol*.2015; 1297–1314
17. Dong L, Huijuan L, Li Wei, Song Z, Li L, Zhou S. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. *Oncotarget*. 2016; Vol. 7(22) : 1 – 16
18. Au KM, Wang AZ, Park SI. Pretargeted delivery of PI3K / mTOR small-molecule inhibitor – loaded nanoparticles for treatment of non-Hodgkin’s lymphoma. *Sci Adv*. 2020;7:1–13.
19. Batlevi C, Younes A. Revival of PI3K inhibitors in non-Hodgkin’s lymphoma. *Ann Oncol*. 2017;28(9):2047–9.
20. Dreyling M, Morschhauser F, Bouabdallah. Pahase II study of copansilib, a p13K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. *Ann Oncol*.2017;28(9): 2169 – 2178.
21. Merryman RW, Armand P, Wright KT, and Rodig SJ. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. *The American Society of Hematology*. 2017;1 (26): 2643–2654.

22. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ and Timmerman JM. Programmed Death Ligand 1 is expressed by Non-Hodkin Lymphomas and inhibits the Activity of Tumor- Associated T cells. *Human Cancer Biology*. 2011;17(13) : 4232–4244.
23. Alsaab H, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw Sk et al. PD-1 and PD-L1 Checkpoint Signlaing Inhibition for cancer immunotherapy : Mechanism, Combinations and Clinical Outcome. *Frontiers in Pharmacology*. 2017;8 : 1– 15.
24. Chen Q,Li T, Yue W. Drug response to PD-1/PD-L1 blockade : based on biomarkers. *Onco taregts and therapy*. 2018;11: 4673 – 4683.
25. Laurent C, Fabiani B, Do C, Tehernonog E, Catron G, Gravelle P et al. Immune-checkpoint expression ini Epstein-Barr virus positive and negative plasmablastic lymphoma. *Haematologica*.2016;101:976 – 84.
26. Kwon D, Kim S, Kim PJ, Go H,Nam SJ, Park JH et al. Clinicopatholical analysis of programmed cell death 1 and programmed cell ligand expression in the tumor microenvironment of diffuse large B cell lymphomas. *Journal of Histopathology*.2016;68:1079 – 89.
27. Song MK, Park B, Uhm J. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-Cell Lymphoma.*Int Journal Mol Sci*.2019;1 –16.
28. Gravelle P, Burroni B, Pericart S, Rossi C, Bezombes C, Tosolini M et al. Mechanism of PD-1/PD-L1 expression and prognostic relevance in non-hodgkin lymphoma : a summary of immunohistochemical studies.*Impact Journal*.2017;27 : 44960 – 44975.
29. Fadjari H, Oehadian A. *Dasar-dasar biologis limfoproliferatif*. Buku Ajar Ilmu Penyakit Dalam Jilid III. Edisi VI. Jakarta; Pusat Penerbitan Ilmu Penyakit Dalam. 2014
30. Stenson M. *Diffuse large B-cell lymphoma – proteomic and metabolomic studies on prognosis and treatment failure*. University of Gothenburg.2018;1–18 .

31. Choi Y, Hoon LD, Yu JI, Jo K, Nam HD, Seol HJ. Prognostic value of Ki-67 labeling Index and Postoperative Radiotherapy in WHO grade II Meningioma. *American Journal Oncology*. 2015;1–8
32. Rahimi H, Borojerdi ZR, Azimi SA, Rahidin E, Jafarian A. Prognostic significance evaluation of B-cell lymphoma 2 (BCL2) and Ki67 Expression in diffuse large B-cell lymphoma patients. *Immunopathol Persa*. 2020;6:1–7.
33. Bertics P, Koziol C, Wiepzig G. Signal transduction by the B cell antigen receptor and its coreceptors. *Immunol*. 2000;129–131
34. Akinleye A, Awaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3 kinase (PI3K) inhibitors as cancer therapeutic. *J Hematol Oncol*. 2013;(6):88
35. Saedi B, Razmpa E. Clinical feature of extranodal presentation of non hodgkin lymphoma in head and neck. *Acta Medica Iranica* 2009;47(6): 489–92
36. Fan X, Zhou X, Wang X. Clinical development of phosphatidylinositol 3-kinase inhibitors for non hodgkin lymphoma. *Biomarker Research*. 2013.1–30
37. So L, Fruman D. PI3K signaling in B and T Lymphocytes; new developments and therapeutic advances. *Biochem J*. 2012; 442(3) 465–81
38. Blachly J, Robert A. Baiocchi. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. *Br J of Haematol*. 2014;167: 19–32
39. Xu Z, Li J, Wang A, Hu J. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma; clinical significance and inhibitory effect of rituximab. *Ann Hematol*. 2013; 92
40. Fowler N, Davis E. Targeting B cell receptor signalling changing the paradigm. *ASH Education Book*. 2013;553–60
41. Hong J, Hong M, Choi K, Kim Y, Chang W, Maeng C et al. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma; a clinicopathological study of 262 cases. *Ann Oncol*. 2014; 25: 182–8
42. Blachly J, Robert A. Baiocchi. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. *Br J of Haematol*. 2014;167: 19–32

43. Vivanco I, Sawyers CL. The Phosphatidylinositol 3 kinase AKT pathway in human cancer. *Nat Rev Cancer*. 2002;2 (7): 489-501.
44. Aritta A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Brody JD. Signaling pathways in lymphoma; pathogenesis and therapeutic targets. *Future Oncol*. 2013;1549–71
45. Gopal, Ajay K, Kahl B, Langdon L, Holes L, Davies A et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *The N Engl J Med*. 2014;370–11
46. Wang, Rule S, Goy A, Martin P, Kahl B, Williams M et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*. 2013; 369:507–16
47. Kutsch N, Marks R, Ratei R, Held TK, Schmidt-Hieber M. Role of tyrosine kinase inhibitors in indolent and other mature B-cell neoplasms. *Libertas Academica*. 2015;10: 15–23
48. Chong E, Lake C, Downs H, Nasta S, Olin R. The Impact of rituximab resistance on overall survival rate in low grade follicular lymphoma. *Blood J*. 2008;1123783
49. Chao P. Treatment challenges in the management of relapsed or refractory non-hodgkin's lymphoma—novel and emerging therapies. *Cancer Management and Research* 2013;5 251–69
50. Hess, G. Houftrock B. Rituximab in the treatment of non hodgkins lymphoma. *Biologic*. 2018;619–33
51. Weiner GJ. Rituximab: mechanism of action. *Semin Hematol*. 2010;47(2):115–23
52. Tomas J, Jana M, Michal K, Juraj D and Roman H. Pd-1/PD-L1 inhibitors in haematological malignancies: update 2017. Department of Hematooncology, University Hospital Ostrava, Czech Republic. 2017;1:1–16.
53. Bardhan K, Anagnostou T, and Boussiotis VA. The PD1 : PD-L1/2 Pathway from Discovery to Clinical Implementation. *Frontiers in immunology*. 2016;7: 1–17.



54. Ohaegbulam KC, Assal A, Molnar AL, Yaou Y, and Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-11 pathway. *Trends in Molecular Medicine*. 2014; xx: 1– 10
55. Gravelle P, Burrioni B, Pericart S, Rossi C, Bezombes C, Tosolini M et al. Mechanism of PD-1/PD-L1 expression and prognostic relevance in non-hodgkin lymphoma : a summary of immunohistochemical studies. *Impact Journal*.2017;27:44960–44975.
56. Chen RQ, Liu F, Qiu YY, Chen Xq. The prognostic and therapeutic value of PDL-1.*Frontier farmacology*.2019;9:1503.
57. Xing W,Dresser K, Zhang R, Evens AM, Yu H,Woda AB et al. PD-L1 expression in EBV-negative diffuse large B-Cell lymphoma : clinicopathologic features and prognostic implications.*Impact Joournal*. 2017;59976–59986
58. Xia Y, Medeiros J, Young KH. Signaling Pathway and dysregulation of PD1 and its signal in Lymphoid Malignancies.*HHS Public Access*.2016;1–22.
59. Schwartz, Zhang Y, Rosenblatt JD. B cell regulation of the anti tumor response and role in carcinogenesis. *Biomed Central*. 2016;1–15
60. Schmidt J, Blum HE, Thimme R. T-Cell responses in Hepatitis B and C virus infection : similarities and differences. *Emerging Microbes and Infections*.2013;e15;1–8.
61. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of Non-Hodgkin’s Lymphoma. *medical science*. 2021; 9: 1–9.
62. Yin X, Xu A, Fan F, Huang Z, Cheng Q, Zhang L et al. Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma : An Analysis of the Surveillance, Epidemiology, and End Results Database.*Frontiers in Oncology*.2019;1–18
63. Anggorowati N, Indrawati. Hubungan prevalensi subtype molekuler ABC/GCB dengan karakteristik klinis pasien Diffuse Large B- Cell Lymphoma di RSUD Sardjito Tahun 2012.2014. Universitas Gajah Mada.2016;1–6
64. Bakhshi T, George PT. Genetic and epigenetic determinants of diffuse large B Cell Lymphoma. *Blood Cancer Journal*.2020; 1–8

65. Jia C, Liang L, Yang L, Zhao F, Bai J. Expression levels of TWISTS1 are associated with the clinical pathological stage of B cell non Hodgkin Lymphoma. *Exp Ther Med.* 2014;8:1489–93.
66. Rachon D, Mysliwska J, Suchecka-Rachon K, Wieckiewicz J, Mysliwski A. Effect of estrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. *J Endocrinol.* 2002;172: 387–95.
67. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Muller-hermelink HK, Bast M et al. Non Hodgkin lymphoma in the developing world; review of 4539 cases from the International Non.Hodgkin Lymphoma Classification Project. *Haematologica.* 2016;101(10):1244–50.
68. Shamooun RP, Polus R. Serum lactic Dehydrogenase (LDH) Activity in Lymphomas : Prognostic Significance and Relationship to Presentation, Stage and Histological Type. *Zanco J Med Sci.* 2010;14(1): 85–9
69. Zeng Q, Liu Z, Liu T. Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non -hodgkin lymphoma : a meta-analysis. *BMC cancer.* 2020;20:1–10
70. Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma : a metanalysis. *BMC cancer.* 2019;19:1–12.
71. McCord R, Bolen CR, Koeppen H, Kadel EE, Oestergaad MZ, Nielsen T, et al. PD-L1 and tumor-associated macrophages in de novo DLBCL. 2019. *Blood advances.* 2020; 1–5
72. Samarina SV, Semenova N, Minaeva NV, Dyakonov DA, Rosin VA, Vaneeva EV et al. Value of PD-L1 Protein Expression in the Combined Prognostic Model of Diffuse Large B-Cell Lymphoma. *Onco Clinical Hematology.* 2021; 1493 : 308–14.
73. Meena M, Mehta J. Association of Ki-67 Proliferative Index with Clinico-Pathological Features of Non-Hodgkin's Lymphoma Classified According to WHO (2008). *International journal of Medical Research Professionals.* 2016;2(4): 103–07.

74. Rahimi H, Borojerdi ZR, Azimi SA, Rashidian E, Jafarian A. Prognostic significance evaluation of B-Cell lymphoma 2 (BCL2) and Ki-67 expression in diffuse large B-cell lymphoma patients. *Immunopathol Persa*.2020; 6:1–7
75. Hashmi AA, Iftikhar SN, Nargus G, Ahmed O, Asghar IA, Shirazi UA et al. Ki67 proliferation index in germinal and non germinal subtypes of diffuse large B Cell Lymphoma. *cureus journal*.2021:1–10.
76. Zaeim F, Jerbi R, Albanyan O, Puccio J, Kafri Z, Yang J et al. High ki67 proliferation index but not cell of origin subtypes is associated with shorter overall survival in diffuse large B Cell Lymphoma. *Avicenna Journal of Medicine*.2020;241–248.
77. Chong Y, Kim TE, Cho U, Jin MS, Yim K, Thakur N et al. Comparison of Ki-67 labeling index patterns of Diffuse Large B Cell Lymphoma and Burkitt Lymphomas Using Image Analysis : A Multicenter Study. *Diagnostic*.2021;11: 1–12
78. Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomikawa K et al. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). *Lung cancer*. 2016;98:69–75.
79. Qiu XY, Hu DV, Chen WQ, Chen RQ, Qian SR, Li CY et al. PDL1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. *Biochim Biophys Acta Mol Basis*. 2018;1864:1754–69.
80. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B- cell lymphoma. *Blood*.2015;126(19): 2193–2201.